phase ii trial curcumin patients advanced pancreatic cancer pubmed ncbi abstract purpose pancreatic cancer lethal u s food drug administration-approved therapies gemcitabine erlotinib produce objective responses num patients evaluated clinical biological effects curcumin diferuloylmethane plant-derived dietary ingredient potent nuclear factor-kappab nf-kappab tumor inhibitory properties advanced pancreatic cancer experimental design patients received num curcumin mouth daily disease progression restaging num months serum cytokine levels interleukin il num il num il num il num receptor antagonists peripheral blood mononuclear cell expression nf-kappab cyclooxygenase num monitored results twenty-five patients enrolled num evaluable response circulating curcumin detectable drug glucuronide sulfate conjugate forms albeit low steady-state levels suggesting poor oral bioavailability patients showed clinical biological activity ongoing stable disease num months interestingly additional patient marked tumor regression num accompanied significant increases num num fold serum cytokine levels il num il num il num il num receptor antagonists toxicities observed curcumin down-regulated expression nf-kappab cyclooxygenase num phosphorylated signal transducer activator transcription num peripheral blood mononuclear cells patients baseline levels considerably higher found healthy volunteers considerable interpatient variation plasma curcumin levels drug levels peaked num num ng/ml remained constant num weeks conclusions oral curcumin tolerated limited absorption biological activity patients pancreatic cancer 
